Enrich Biosystems
Branford, US · Founded 2018 · Delaware corporation · 1 known investors
Enrich Biosystems develops TROVO, a fluidics-free benchtop instrument that compartmentalizes standard culture plates into thousands of hydrogel microwells for high-throughput functional screening, imaging, and live recovery of cells. It serves cell therapy and life sciences researchers working on applications such as CAR-T cell selection, cell line development, and single-cell omics enrichment.
Founders & leadership
QZ
Qi ZhaoNamed on SEC filing
DW
Dong WangNamed on SEC filing
CG
Cynthia GreenNamed on SEC filing
Board
DW
Daniel WagnerBoard director
CM
Christopher McLeodBoard director
JT
Jay TeichBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$8.2M disclosed across 4 rounds · 2022–2025
▶$1.4MraisedNov 2025 · 4 investors · BiotechnologyRule 506(b)
▶$1.4MraisedNov 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel WagnerDirector
- Qi ZhaoExecutive Officer, Director
- Christopher McLeodDirector
- Dong WangExecutive Officer, Director
- Jay TeichDirector
- Offering amount
- $1.5M
- Amount sold
- $1.4M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$750KraisedMay 2024 · 10 investors · BiotechnologyRule 506(b)
▶$750KraisedMay 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cynthia GreenDirector
- Qi ZhaoExecutive Officer, Director
- Christopher McLeodDirector
- Jay TeichDirector
- Dong WangExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $750K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedMay 2024 · 17 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMay 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Qi ZhaoExecutive Officer, Director
- Cynthia GreenDirector
- Dong WangExecutive Officer, Director
- Christopher McLeodDirector
- Jay TeichDirector
- Offering amount
- $3.1M
- Amount sold
- $2.2M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedJun 2022 · 26 investors · BiotechnologyRule 506(b)
▶$3.8MraisedJun 2022 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cynthia GreenDirector
- Jay TeichDirector
- Christopher McLeodDirector
- Qi ZhaoExecutive Officer, Director
- Dong WangExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $3.8M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Enrich Biosystems for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Enrich Biosystems do?
- Enrich Biosystems develops TROVO, a fluidics-free benchtop instrument that compartmentalizes standard culture plates into thousands of hydrogel microwells for high-throughput functional screening, imaging, and live recovery of cells. It serves cell therapy and life sciences researchers working on applications such as CAR-T cell selection, cell line development, and single-cell omics enrichment.
- Who are Enrich Biosystems's investors?
- Enrich Biosystems's investors include Connecticut Innovations.
- How much funding has Enrich Biosystems raised?
- Enrich Biosystems has disclosed $8.2M raised across 4 rounds.
- Where is Enrich Biosystems headquartered?
- Enrich Biosystems is headquartered in Branford, US.